Page 4 - Valued Shareholders News Today

Provided $1.9 million of funding to IMC for the further advancement of the RapidSX technology for commercial deployment; including a $1-million tranche transferred on April 26, 2021Allocated funding for

Ucore Chairman & CEO Provides Strategic Update to Shareholders: Taking Action Today to Secure Tomorrow Provided $1.9 million of funding to IMC for the further advancement of the RapidSX™ technology for commercial deployment; including a $1-million tranche transferred on April 26, 2021Allocated funding for an Independent Evaluation of RapidSX™ technology for the separation of REEs – scheduled for completion in Summer 2021Allocated $750,000 to further ongoing specific business-development a...

Turnkey Capital Inc.: Turnkey Capital Issues February 2021 Shareholder Update Dear Valued Shareholders, I would like to start by thanking each of you for your continued support of Turnkey. I believe we have a great opportunity and the right team to execute our plan. Today I would like to share some background information, accomplishments to date and our path forward. After years of helping companies achieve growth and profitability and seeing how devastated businesses were at the onset of COVID...

LOS ANGELES, CA / ACCESSWIRE / February 11, 2021 / Radiko Holdings (CSE:RDKO) (the "Company") CEO Steve Gormley publishes an open letter to Shareholders. To Our Valued Shareholders, Last month I shared

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Herborium® Group Inc, Shareholders Update Letter Herborium Group IncJanuary 8, 2021 GMT Fort Lee, New Jersey, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Herborium® Group, Inc. (OTC Pink: HBRM ),  www.Herborium.com, www.acnease.com a Botanical Therapeutics ® Company and the provider of proprietary all botanical medicinal products (Botanical Therapeutics®) and interactive advanced content targeting dermato...

BrainStorm Issues 2020 Letter to Shareholders USA - English Share this article Share this article NEW YORK, Dec. 28, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI),  a leading developer of cellular therapies for neurodegenerative diseases, today announced the following letter from its Chief Executive Officer, Chaim Lebovits, to its shareholders and the investment community. Dear Valued Shareholders, I am incredibly proud of the tremendous progress BrainStorm made as a...